Treatment Patterns Among Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Secondand Third-Line Therapy in a Medicare Population

被引：0
|
作者：
Tkacz, Joseph [1 ]
Gorsh, Boris [2 ]
Molinari, Alexa [2 ]
Boytsov, Natalie [2 ]
Wang, Peter Feng [2 ]
Perera, Sue [3 ]
Landi, Suzanne [2 ]
Hanna, Maya [2 ]
Johnson, William [1 ]
Schroeder, Amy [1 ]
Paka, Prani [2 ]
机构：
[1] Inovalon, Bowie, MD USA
[2] GlaxoSmithKline, Providence, RI USA
[3] GlaxoSmithKline, London, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
MM; relapsed/refractory multiple myeloma; treatment; patterns; drug classes; Medicare; retreatment;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-451
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [31] Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)
    Hawkins, Neil
    Ramasamy, Karthik
    Dhanasiri, Sujith
    [J]. BLOOD, 2018, 132
  • [32] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [33] SLR OF ECONOMIC EVALUATION FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN UK
    Mehta, J.
    Harrison, O.
    Barwood, C.
    Ubi, S.
    Bertranou, E.
    Bouhlabel, F.
    Low, E.
    Shah, A.
    Korde, R.
    Shah, J.
    Gaugris, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S51 - S52
  • [34] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Abadier, Michael
    Estevam, Jose
    Berg, Deborah
    Fedyk, Eric Robert
    [J]. BLOOD, 2020, 136
  • [35] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    [J]. HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [36] Real world treatment patterns and outcomes for mNSCLC patients receiving second and third-line therapy in Germany
    Yu, N.
    Reyes-Rivera, I.
    Hipp, J.
    Zou, M.
    Pillai, N.
    Hammerschmidt, S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [37] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    [J]. HAEMATOLOGICA, 2016, 101 : 538 - 539
  • [38] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Ibrahim, Emad
    Vallurupalli, Anusha
    Cull, Elizabeth H.
    Green, Damian J.
    Oliver, Kate
    Longcor, Jarrod
    [J]. BLOOD, 2019, 134
  • [39] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [40] Targeted Therapy Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    [J]. ONCOLOGY-NEW YORK, 2021, 35 (05): : 284 - 287
12345